Sedloev T, Gabrovski I, Usheva S, Kovacheva S, Spiridonova Ts, Spirdonov J, Jeleva Z, Terziev I, Korukov B, Damyanov D, Lövey G
Khirurgiia (Sofiia). 2016;82(1):40-4.
The intraoperative radiotherapy (IORT) is an innovative method for treatment of breast cancer, which can be used as a substitute of postoperative external beam radiotherapy )EBRT), or boost treatment to EBRT (1). Radiobiological advantages of IORT compared to EBRT are higher relative biologic effectiveness of low-dose radiation therapy and the presence of high dose in the tumor bed (where the possibility of remaining vital tumor cells is the highest), as this dose reduces rapidly with the distance from the applicator (2). Important feature of IORT alone is that it can be applied as a single fraction during the surgical intervention and spares 3 to 5 weeks of following radiation therapy. This means less time spent in hospital for the patients and for the radiotherapeutical units - reduced waiting lists and more machine time for other patients. Prolonged operative time as well as the need of additional staff are assumed as relative flaws of IORT (3). The INTRABEAM® system (Carl Zeiss Surgical Gmbh, Oberkochen, Germany) uses a single high dose of low-energy X-rays (mas 50kV), applied to the tumor bed immediately after the surgical excision of the tumor. These rays have high degree of absorption and low penetrating ability. This determines their advantage in comparison to EBRT to protect the surrounding healthy tissues (2). The data from the Targeted Intraoperative radioTherapy (TARGIT-A) and the Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ELIOT): a randomized controlled equivalence trial show that when following the recommendations of The Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) Breast Cancer Working Group (2009) for an accelerated partial breast irradiation (APBI), IORT can be used as an equivalent of the postoperative radiotherapy (1,4,5,6). The purpose of this article is to show the results of the performed on 15 December 2015 for the first time in Bulgaria breast conserving surgery with intraoperative radiotherapy on a patient with early breast cancer.
术中放疗(IORT)是一种治疗乳腺癌的创新方法,可替代术后外照射放疗(EBRT),或作为EBRT的补充治疗(1)。与EBRT相比,IORT的放射生物学优势在于低剂量放疗的相对生物效应更高,且在瘤床(残留存活肿瘤细胞可能性最高的部位)存在高剂量,因为该剂量会随着与施源器距离的增加而迅速降低(2)。IORT单独使用的一个重要特点是,它可在手术干预期间作为单次分割应用,从而省去后续3至5周的放疗。这意味着患者和放疗单位住院时间减少——等待名单缩短,其他患者有更多的机器使用时间。手术时间延长以及需要额外的工作人员被认为是IORT的相对缺点(3)。INTRABEAM®系统(德国奥伯科亨的卡尔蔡司外科有限公司)使用单次高剂量的低能X射线(最大50kV),在肿瘤手术切除后立即应用于瘤床。这些射线具有高度吸收性和低穿透能力。这决定了它们与EBRT相比在保护周围健康组织方面的优势(2)。靶向术中放疗(TARGIT - A)和早期乳腺癌术中放疗与外照射放疗对比:一项随机对照等效性试验的数据表明,遵循欧洲近距离治疗协会 - 欧洲治疗放射学和肿瘤学会(GEC - ESTRO)乳腺癌工作组(2009年)关于加速部分乳腺照射(APBI)的建议时,IORT可作为术后放疗的等效替代方法(1,4,5,6)。本文的目的是展示2015年12月15日在保加利亚首次对一名早期乳腺癌患者进行保乳手术并术中放疗的结果。